Evidence map›Paper›PMID 33946817›Full record

ArticlePathogens (Basel, Switzerland)2021

Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test.

Anna Colombo, Mauro Giuffrè, Lory Saveria Crocè, Sergio Venturini, Renato Sablich

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Anna ColomboDepartment of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy.
Mauro GiuffrèDepartment of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy.ORCID 0000-0002-9910-3514
Lory Saveria CrocèDepartment of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy.ORCID 0000-0001-9890-7011
Sergio VenturiniDepartment of Infectious Diseases, Azienda Sanitaria Friuli Occidentale, Pordenone Hospital, 33170 Pordenone, Italy.ORCID 0000-0003-0271-0826
Renato SablichIBD Unit, Department of Gastroenterology, Azienda Sanitaria Friuli Occidentale, Pordenone Hospital, 33170 Pordenone, Italy.
University of Trieste · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infliximab is an IgG1 antitumor necrosis factor monoclonal antibody that is commonly used to treat inflammatory bowel disease (IBD) and other autoimmune disorders. However, it is known to increase the risk of reactivation of latent tuberculosis (LTBI) due to its capability to disrupt TB granulomas. We describe a case of extrapulmonary TB in a patient with ulcerative colitis who was treated with Infliximab after a negative Quantiferon Test. In addition, we report briefly on the current controversy about the appropriateness, interval, and methods for the repeated screening of latent TB in IBD patients that are treated with antitumor necrosis factor alpha (TNF-α) antibodies.

Indexed as

inflammatory bowel diseaseInfliximabperitoneal tuberculosisQuantiferon

Identifiers

PMID33946817
PMCPMC8145928
OpenAlexW3157805227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.